Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM
Status:
Completed
Trial end date:
2020-10-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy of Lenalidomide versus
Placebo maintenance following melphalan, prednisone and velcade induction therapy in newly
diagnosed multiple myeloma.
After the study is unblinded, subjects in treatment Arm A (Len 10 mg) will remain on study
therapy at the Investigator's discretion and subjects in treatment Arm B (placebo), will be
discontinued from study treatment. Subjects who discontinued from study treatment for any
reason will enter the LTFU Phase.